July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Uveal complications of MEK and BRaf inhibition
Author Affiliations & Notes
  • Tara McCannel
    Jules Stein Eye Institute UCLA, Los Angeles, California, United States
  • Footnotes
    Commercial Relationships   Tara McCannel, Impact Genetics (C), Novartis Pharmaceuticals Inc (C)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 4410. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Tara McCannel; Uveal complications of MEK and BRaf inhibition. Invest. Ophthalmol. Vis. Sci. 2018;59(9):4410.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Presentation Description : The approval of MAP Kinase pathway inhibitors for the treatment of metastatic cancer has resulted in the recognition of specific ocular toxicities in certain cases. The most common ocular toxicity is the development of focal neurosensory retinal detachment of the macula, most readily detectable by OCT. Uveitis may also occur as a result of MEK and BRAF inhibitors together with neurosuensory retinal detachment or on its own. This uveitis is usually asymptomatic and detectable only by clinical examination. Treatment involves periocular steroid and the uveitis may persist long after discontinuation of MEK inhibition. Diagnosis and management of these and other ocular toxicities will be discussed.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.